Canagliflozin is a highly effective and selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), primarily used in the treatment of type 2 diabetes mellitus. Below is a detailed introduction to Canagliflozin:
Basic Information
English Name: Canagliflozin
Chemical Structure: C24H25FO5S
Molecular Weight: 444.52
CAS Number: 842133-18-0
Pharmacological Action
Canagliflozin works by inhibiting SGLT2 in the kidneys, reducing the reabsorption of glucose from urine, and thereby increasing urinary glucose excretion to lower blood glucose levels. SGLT2 is a glucose transporter primarily located in the renal tubules, responsible for reabsorbing glucose from urine back into the bloodstream. By inhibiting SGLT2, Canagliflozin allows more glucose to be excreted in urine, achieving a reduction in blood glucose.
Indications
Primarily used for the treatment of type 2 diabetes mellitus, particularly in patients who fail to achieve glycemic control through diet and exercise alone.
Can be used in combination with metformin or other drugs to improve glycemic control.
Besides its glucose-lowering effects, Canagliflozin has also been shown to reduce the risk of cardiovascular events and protect kidney function.
